Wegovy week 1: Is 1 pound per week a realistic loss rate?

What's this video probably claiming?

Based on the caption, this creator is documenting their first week on the 0.5mg semaglutide dose (the standard starting dose for Wegovy), reporting a one-pound loss, and expressing mild disappointment, partly attributing the lower number to nausea blunting their appetite less predictably than expected. This is a classic early-journey GLP-1 post: honest, relatable, and drawing an implicit causal line between the drug, the nausea side effect, and the scale result. The video is almost certainly framing nausea as a sign the medication is "working" and suggesting that more nausea should logically produce more weight loss. That framing is worth examining carefully, because it's not how semaglutide actually works physiologically, and it sets up expectations that can derail adherence when the dose-titration phase doesn't deliver dramatic results.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) is the landmark semaglutide 2.4mg trial. Participants lost a mean of 14.9% body weight over 68 weeks, but that number obscures what happens at the beginning. The titration phase, which runs through weeks 1 to 16, involves doses from 0.25mg to 1.0mg, and weight loss during this period is modest by design. The therapeutic dose is 2.4mg. At 0.5mg, you are not yet at a pharmacologically meaningful weight-loss dose. Nausea at low doses is largely a central nervous system response to GLP-1 receptor activation in the brainstem, not a direct proxy for fat loss. A 2022 analysis by Kushner et al. in Obesity confirmed that nausea severity does not reliably predict magnitude of weight loss, and that patients who experienced more nausea did not consistently lose more weight than those who tolerated the drug well.

Where does the social media noise diverge from clinical reality?

GLP-1 content on TikTok overwhelmingly treats the scale as a week-by-week performance metric, which creates a distorted feedback loop. One pound in week one is not a failure; it's within normal range for a sub-therapeutic dose. The STEP trials show meaningful weight loss accelerates after week 16 once patients reach 1.7mg and especially 2.4mg. The community also reinforces the nausea-equals-results myth persistently. Posts celebrating nausea as a badge of effectiveness are common, but clinically, nausea is a tolerability issue, not a therapeutic signal. Persistent severe nausea at 0.5mg is actually a reason to discuss slower titration with a prescriber, not a reason to feel optimistic about the number on the scale. The hashtag ecosystem here, including terms like "wegovyresults" and "glp1community," creates a social comparison environment that the actual trial data does not support at this stage of treatment.

What should you actually know?

If you're starting Wegovy or any semaglutide product, week one on 0.5mg is titration, not treatment. The dose is designed to build tolerance, not drive fat loss. Expecting significant weight loss this early is a setup for unnecessary frustration. Nausea is manageable and should be discussed with your prescriber if it's affecting your quality of life; it is not something to celebrate or use as a proxy for efficacy. The real weight-loss trajectory on Wegovy is a slow curve that steepens considerably between months four and twelve. Davies et al. (2021, The Lancet) confirmed sustained dose-dependent weight loss across the STEP program, but "sustained" is the key word. Short-term fluctuations, water retention shifts, and hormonal cycles all affect weekly weigh-ins far more than any single dose adjustment. One pound down in week one is not disappointing. It's appropriate.